New research indicates that a placebo, which is similar to an anti-depressant, can "trick" the brain into responding in the same manner as the real drug.
A new study by the University of California Los Angeles (UCLA) shows that the brain may be influenced by its remembrance of past exposure to such drugs.
Depression
Depression is one of the most common mental disorders affecting approximately 340 million people in the world. No one is immune from depression - it occurs in people of all social classes, all countries and all cultural settings.
Advertisement
Aimee Hunter, assistant professor of psychiatry at the UCLA and colleagues examined the brains of 89 depressed persons during eight weeks of treatment, using either an anti-depressant or a similar-looking placebo, the journal European Neuropsychopharmacology reports.
Individuals who suffer from major depressive disorder often undergo multiple therapies with anti-depressants, according to an UCLA statement.
This is because the disorder can recur in spite of treatment and because finding the right drug for a specific individual can take time.
Source: IANS
This is because the disorder can recur in spite of treatment and because finding the right drug for a specific individual can take time.
Source: IANS
Adolescent Depression
Adolescent depression is an ailment that occurs during the teenage characterized by persistent melancholy, disappointment and loss of self-esteem.
Advertisement
 Holistic Management for DepressionDepression is a common disorder and many worldwide suffer from depression. Early recognition of symptoms and signs of depression can help in taking a holistic approach to the management of depression. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.